{"DataElement":{"publicId":"5154372","version":"1","preferredName":"PR Status Other Method Not IHC Performed Text","preferredDefinition":"Text field to describe the specific method used to determine the patient's progesterone receptor (PR) status, other than immunohistochemical (IHC) staining.","longName":"5154197v1.0:2181231v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"5154197","version":"1","preferredName":"Progesterone Receptor Status Other Method Negation Immunohistochemistry Staining Method Performed","preferredDefinition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)._Different than the one(s) previously specified or mentioned._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal._An operation in which a term denies or inverts the meaning of another term or construction._Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen._Executed and carried through to completion.","longName":"5154195v1.0:5154192v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"5154195","version":"1","preferredName":"Progesterone Receptor Status","preferredDefinition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","longName":"C16149","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progesterone Receptor Status","conceptCode":"C16149","definition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC94499-08FC-9472-E050-BB89AD431704","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-03-11","modifiedBy":"ONEDATA","dateModified":"2016-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5154192","version":"1","preferredName":"Other Method Negation Immunohistochemistry Staining Method Performed","preferredDefinition":"Different than the one(s) previously specified or mentioned.:A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.:An operation in which a term denies or inverts the meaning of another term or construction.:Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.:Executed and carried through to completion.","longName":"5154192v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Method","conceptCode":"C71460","definition":"A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Immunohistochemistry Staining Method","conceptCode":"C23020","definition":"Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC924A2-1C2C-CD6C-E050-BB89AD4358FB","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-03-11","modifiedBy":"ONEDATA","dateModified":"2016-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DC94499-090A-9472-E050-BB89AD431704","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-03-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for TCGA BRCA CDF form per request by K.Wildermuth. mc 3/11/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2181231","version":"1","preferredName":"Descriptive Text","preferredDefinition":"The text that provides a description of a topic.","longName":"DESCR_TXT","context":"DCP","contextVersion":"1","type":"Non-enumerated","dataType":"ALPHANUMERIC","minLength":"1","maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D3B72801-8C4C-3772-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2004-02-19","modifiedBy":"GDEEN","dateModified":"2022-05-31","changeDescription":"3/22/22 jk added \"Qualified\" RS as part of MCL quarterly content review.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"If a method other than IHC wa","type":"Preferred Question Text","description":"If a method other than IHC was used to determine PR Status, what method was used?","url":null,"context":"NCIP"}],"origin":"CTSP/CDDP: Clinical Trial Sequencing and Cancer Driver Discovery Projects","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DCCE006-3A05-0E37-E050-BB89AD435604","latestVersionIndicator":"Yes","beginDate":"2016-03-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-03-11","modifiedBy":"COOPERM","dateModified":"2016-10-03","changeDescription":"Created for BRCA CDF per request by K.Wildermuth. mc 3/11/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}